Immunotherapy before surgery for MMRd stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests two immunotherapy drugs, zimberelimab and domvanalimab, given before surgery for people with a specific type of stomach cancer (called MMRd/MSI-H). The goal is to see if these drugs can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with a type of stomach or junction cancer (where the stomach meets the esophagus).
- Your tumor has a specific genetic feature called MMRd or MSI-H (a test can tell this).
- Your cancer is at stage II or III and has not spread to other parts of the body (like the liver or lungs).
- Your doctors believe surgery can remove all of the cancer after you receive treatment first.
- You have not had any prior treatment for this stomach cancer, and you are in generally good health (able to do daily activities without major help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests pembrolizumab (an immunotherapy medicine) given before curative surgery in people with certain MMR-deficient colon or rectal cancers. It aims to shrink or control the cancer so surgery can be done more effectively, and to see if outcomes improve compared with standard care.
This trial tests whether giving immunotherapy before surgery can help people with a specific type of stomach cancer (dMMR/MSI-H) that can be removed. It aims to see how well the immune system responds and if the tumor shrinks.
This trial tests two immunotherapy drugs given before surgery for locally advanced gastric cancer that has a specific genetic marker (MSI-H or dMMR). The goal is to shrink the tumor and improve outcomes before removing it surgically.
This trial tests a new immunotherapy drug (adebrelimab) combined with chemotherapy or another drug (SHR-8068) for a specific type of advanced stomach cancer that has a genetic marker called dMMR or MSI-H. The goal is to see if these combinations can make the tumor shrink enough to be removed with surgery.
This trial tests combining an immunotherapy drug (sintilimab) with low-dose radiation before surgery for stomach cancer that has a specific genetic marker (dMMR/MSI-H). The goal is to see if this combination can shrink the tumor and improve outcomes without needing strong chemo.
This trial tests whether adding an immunotherapy drug (QL1706) to a standard chemotherapy regimen, given before surgery, can help shrink stomach or gastroesophageal junction cancer. The goal is to improve the chance of successful surgery and long-term outcomes.
Hear when a new Locally Advanced Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.